Adenovirus-mediated Transfer of a p53 Gene in Ovarian Cancer
作者： Junzo Kigawa , Naoki Terakawa
关键词: Ovarian cancer 、 Gene 、 Recombinant DNA 、 Medicine 、 Cancer research 、 Cell growth 、 Cancer gene 、 Cisplatin 、 Gene transfer 、 INVESTIGATIONAL GENE THERAPY
摘要: Given the lack of effective conventional therapy, those patients with recurrent or refractory ovarian cancer should be considered for currently approved investigational gene therapy protocols. Several studies have shown a potential modality p53 transfer in therapy. We also developed new recombinant adenovirus carrying wild-type (AxCAp53). Although efficacy AxCAp53 to suppression cell growth was not sufficient, increased sensitivity CDDP cells deletion gene. The combination and may strategy resistant cancer.
springer.com
sci-hub.se 参考文章(39)
Jordan U. Gutterman, Kalpana Mujoo, Scott C. Anderson, Daniel C. Maneval, Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene. ,vol. 12, pp. 1617- 1623 ,(1996)
John A. Kellen, Molecular Interrelationships in Multidrug Resistance Birkhäuser Boston. pp. 215- 223 ,(1995) , 10.1007/978-1-4615-9852-7_11
Raymond P. Perez, Thomas C. Hamilton, Robert F. Ozols, Robert C. Young, Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. Cancer. ,vol. 71, pp. 1571- 1580 ,(1993) , 10.1002/CNCR.2820710424
G Brandner, M Fritsche, C Haessler, Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene. ,vol. 8, pp. 307- 318 ,(1993)
Mace Rothenberg, Gi-Ming Lai, Antonio Fojo, Robert F. Ozols, Thomas C. Hamilton, Hidetaka Masuda, Increased DNA Repair as a Mechanism of Acquired Resistance to cis-Diamminedichloroplatinum(II) in Human Ovarian Cancer Cell Lines Cancer Research. ,vol. 48, pp. 5713- 5716 ,(1988)
Kazuhide Komiya, Tamotsu Matsuda, Kazuto Nishio, Tohru Ohmori, Nagahiro Saijo, Yasuhiro Fujiwara, Yasuhiro Fujiwara, Yoshikazu Sugimoto, Kazuo Kasahara, METALLOTHIONEIN CONTENT CORRELATES WITH THE SENSITIVITY OF HUMAN SMALL CELL LUNG CANCER CELL LINES TO CISPLATIN Cancer Research. ,vol. 51, pp. 3237- 3242 ,(1991)
Mack N Barnes, Jessy S Deshane, Gene P Siegal, David T Curiel, Ronald D Alvarez, Gene therapy and ovarian cancer: A review Obstetrics & Gynecology. ,vol. 89, pp. 145- 155 ,(1997) , 10.1016/S0029-7844(96)00296-7
Shi-Jiang Lu, Shan Man, Maria R Bani, Dena Adachi, Robert G Hawley, Robert S Kerbel, Yaacov Ben-David, None, Retroviral insertional mutagenesis as a strategy for the identification of genes associated with cis-diamminedichloroplatinum(II) resistance. Cancer Research. ,vol. 55, pp. 1139- 1145 ,(1995)
Claudia Caserini, Marco A. Pierotti, Monica Giarola, Rosanna Supino, Paola Perego, Sabina C. Righetti, Franco Zunino, Domenico Delia, John C. Reed, Toshiyuki Miyashita, Association between Cisplatin Resistance and Mutation of p53 Gene and Reduced Bax Expression in Ovarian Carcinoma Cell Systems Cancer Research. ,vol. 56, pp. 556- 562 ,(1996)
Ken-Ichiro Fukuchi, Mark G. Hearn, Samir S. Deeb, Annette C. Smith, Ngocthao Dang, Jun-Ichi Miyazaki, Mark Bothwell, George M. Martin, Activity assays of nine heterogeneous promoters in neural and other cultured cells In Vitro Cellular & Developmental Biology – Animal. ,vol. 30, pp. 300- 305 ,(1994) , 10.1007/BF02631450